Approval · Notice of Compliance 14956 · 2013
NESINA: Notice of Compliance 14956
Issued November 27, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14956
- Date
- November 27, 2013
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Oral antihyperglycemeic agent; dpp-4 inhibitor; incretin enhancer
Products in this notice
Medicinal ingredients
- ALOGLIPTIN BENZOATE 6.25 MG per TAB
- ALOGLIPTIN BENZOATE 12.5 MG per TAB
- ALOGLIPTIN BENZOATE 25 MG per TAB